Posted by Michael Wonder on 10 Jul 2022
COVID-19 oral treatment eligibility expanded from 11 July 2022
10 July 2022 - From 11 July 2022, more Australians at higher risk of developing severe COVID-19 will be able to access oral anti-viral treatments following new recommendations from the PBAC.
The prescription only oral treatments, Paxlovid and Lagevrio, have been found to be effective in treating mild to moderate COVID-19 in adults aged 18 years of age and older, who do not require supplemental oxygen, and who are at increased risk of progressing to hospitalisation.
